|
WO2020163685A1
|
|
Methods for treating intracranial hemorrhage and assessing efficacy
|
|
US2019388406A1
|
|
Methods of prevention and treatment of thrombosis
|
|
CN112074271A
|
|
Methods for treating lymphoma
|
|
EP3788033A1
|
|
Synthesis of cerdulatinib
|
|
EP3788035A2
|
|
Solid forms of cerdulatinib
|
|
TW202002980A
|
|
Methods of use and pharmaceutical compositions of a selective SYK inhibitor
|
|
PE20190661A1
|
|
PREPARATION OF DERIVATIVES OF FACTOR XA
|
|
CN108883160A
|
|
The lyophilized preparation of factor XA antidote
|
|
US2019119236A1
|
|
Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
|
|
AU2016363005A1
|
|
Cerdulatinib for treating hematological cancers
|
|
WO2017091757A1
|
|
Isotopically enriched betrixaban
|
|
WO2017034990A1
|
|
Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate pcsk9 protein activity
|
|
CN108025013A
|
|
Match degree for treating myeloma replaces Buddhist nun
|
|
EP3302485A1
|
|
Cerdulatinib for the treatment of b-cell malignancies
|
|
AU2015305413A1
|
|
Lyophilized formulations for factor xa antidote
|
|
US2017174673A1
|
|
Pyridazine compounds as JAK inhibitors
|
|
WO2014152768A1
|
|
Cyclohexanediamine compounds and methods for their preparation
|
|
US2014346397A1
|
|
Compounds and methods for purification of serine proteases
|
|
EP2903970A2
|
|
Substituted pyrimidinyl kinase inhibitors
|
|
EP2900243A2
|
|
Bicyclic oxa-lactam kinase inhibitors
|
